The results from the in vivo experiment thus demonstrate the capacity ofReNcells CX to pass the BBB and reach intracranial gliomas and confirm the overexpression of HGF,VEGF and zonulin/prehaptoglobin-2 in gliomas. This evidence concerns the gene VEGFA and central nervous system cancer.